(NASDAQ: VRTX) Vertex Pharmaceuticals's forecast annual revenue growth rate of 10.74% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.93%.
Vertex Pharmaceuticals's revenue in 2026 is $12,001,300,000.On average, 33 Wall Street analysts forecast VRTX's revenue for 2026 to be $3,387,037,855,270, with the lowest VRTX revenue forecast at $3,062,636,194,640, and the highest VRTX revenue forecast at $3,604,237,087,720. On average, 30 Wall Street analysts forecast VRTX's revenue for 2027 to be $3,733,540,490,430, with the lowest VRTX revenue forecast at $3,228,012,452,330, and the highest VRTX revenue forecast at $4,368,371,931,240.
In 2028, VRTX is forecast to generate $4,157,269,519,350 in revenue, with the lowest revenue forecast at $3,238,173,819,930 and the highest revenue forecast at $4,850,782,858,050.